Premium
Large neutral amino acids in the treatment of phenylketonuria (PKU)
Author(s) -
Matalon R.,
MichalsMatalon K.,
Bhatia G.,
Grechanina E.,
Novikov P.,
McDonald J. D.,
Grady J.,
Tyring S. K.,
Guttler F.
Publication year - 2006
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-006-0395-8
Subject(s) - phenylalanine , amino acid , lysine , phenylketonurias , medicine , placebo , phenylalanine hydroxylase , endocrinology , chemistry , biochemistry , pathology , alternative medicine
Summary Large neutral amino acids (LNAAs) have been used on a limited number of patients with phenylketonuria (PKU) with the purpose of decreasing the influx of phenylalanine (Phe) to the brain. In earlier studies on mice with PKU (ENU 2 /ENU 2 ), LNAAs were given and a surprising decline in blood Phe concentrations was observed. The formula used in the mouse experiment (PreKUnil) lacked lysine. Therefore, a new formulation of LNAAs (NeoPhe) was developed, introducing changes in the concentration of some amino acids and adding lysine, so that such a mixture could be used in humans. The new formula was found to be effective in reducing blood Phe concentration in mice by about 50% of the elevated levels. Patients with PKU were given LNAAs and blood Phe concentrations were determined in an open‐label study. Three centres—in Russia, the Ukraine and the USA—took part in the study. NeoPhe was given at 0.5 g/kg per day in three divided doses to eight subjects with PKU and at 1.0 g/kg per day to three patients, for one week. The NeoPhe resulted in decrease of elevated blood Phe by 50% in both groups. The preliminary data from this study are encouraging and a double blind placebo‐controlled trial will be required to show long‐term efficacy and tolerance of LNAAs in the treatment of PKU.